M
Michael S. Broder
Researcher at University of California, Los Angeles
Publications - 213
Citations - 9650
Michael S. Broder is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Health care & Population. The author has an hindex of 37, co-authored 197 publications receiving 8291 citations. Previous affiliations of Michael S. Broder include American Academy of Allergy, Asthma and Immunology & University of Auckland.
Papers
More filters
Journal ArticleDOI
Cost of cancer management by stage at diagnosis among Medicare beneficiaries
Sheila R. Reddy,Michael S. Broder,Eunice Chang,Caleb J. Paydar,Karen Chung,Anuraag R. Kansal +5 more
TL;DR: Beneficiaries diagnosed at later stages of cancer have higher costs of care than those diagnosed at earlier stages, and earlier cancer diagnosis may lead to more efficient treatment and decreased management cost.
Journal ArticleDOI
Treatment patterns in Cushing's disease patients in two large United States nationwide databases: application of a novel, graphical methodology.
Michael S. Broder,Maureen P. Neary,Eunice Chang,Dasha Cherepanov,Gordon H. Sun,William H. Ludlam +5 more
TL;DR: This study addresses a need for US data on real-world treatment patterns for Cushing’s disease patients by analyzing treatment patterns in CD patients in the United States and finding the majority of CD patients undergo surgery as initial therapy.
Journal ArticleDOI
Reply to Schaible
Journal ArticleDOI
Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters using the Modified RAND/UCLA Delphi Process
Renuka Iyer,Susan Acquisto,John Bridgewater,Michael A. Choti,Theodore S. Hong,Bela Kis,Peter A. Mead,Neehar D. Parikh,Lewis R. Roberts,Rebecca Roberts,Riad Salem,Jason K. Sicklick,Richard S. Siegel,Jonathan R. Whisenant,Dasha Cherepanov,Michael S. Broder,Juan W. Valle +16 more
TL;DR: The Delphi process produced consensus guidelines to fill an unmet need in the urgent management of ascending cholangitis in patients with cholangsiocarcinoma and summarized in patients as “appropriate” or “maybe appropriate” based on a patient’s bilirubin level at presentation.
Journal ArticleDOI
Treatment Patterns Among Patients with Myelodysplastic Syndromes: Observations of 1st-Line Therapy, Discontinuation and the Need of Additional Therapies
Sudipto Mukherjee,Christopher R. Cogle,Tanya G. K. Bentley,Michael S. Broder,Eunice Chang,Moira E. Lawrence,Thomas J. McKearn,Scott Megaffin,Rita Percy,Michael E. Petrone,Gordon H. Sun +10 more
TL;DR: A retrospective cohort study using a US commercial health insurance claims database to describe treatment patterns of myelodysplastic syndromes patients who progressed while on, failed to respond to, or became intolerant to hypomethylating agents and were eligible for 2nd-line therapy.